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Collagen-induced arthritis is an animal model of polyarthritis that can be induced 
in susceptible rats by immunization with native type II collagen (1). The development 
of arthritis is associated with high levels of both cell-mediated and humoral immunity 
to  type  II  collagen  (2)  and  the  arthritic  response  appears  to  be  due  to  collagen 
immunity. This animal model is of importance because collagen immunity has also 
been described in association with human rheumatoid arthritis (RA) 1 (3-6) and other 
rheumatic diseases (7, 8). In addition, the histopathology of collagen-induced arthritis 
resembles that seen in human  RA in  that  the lesion is one of synovial proliferation 
that progresses to pannus  formation and results in marginal erosions with extensive 
destruction of cartilage.  Radiographs of affected rat joints also show erosive changes 
similar to those seen in human RA (1). 
The mechanism by which  arthritis  develops in this model is unclear.  It has been 
reported  (9)  that  arthritis  can be transferred  from immunized arthritic  and  nonar- 
thritic  donor  rats  to  nonimmunized  syngeneic  recipients  with  pooled  spleen  and 
lymph node cells. However, the specific cell type responsible for transfer of disease has 
not been identified; furthermore, neither cellular sensitivity nor antibodies to collagen 
could  be  detected  in  the  arthritic  recipients.  We  have  been  impressed  with  the 
invariable association of arthritis with high antibody levels to collagen and decided 
to attempt to transfer disease using serum. Early serum from rats at the time of onset 
of disease was chosen because of the marked difference in anticollagen antibody levels 
in arthritic as compared with nonarthritic  donors  (10)  and the suggestion that early 
serum  was essential  to  transfer of experimental autoimmune  thyroiditis  in  rabbits 
(11). This serum, when fractionated with 50% ammonium sulfate and concentrated, 
proved to be effective in transferring disease. Having successfully transferred disease, 
we addressed the questions of (a) whether the serum factor could reproduce all of the 
histopathologic  findings  present  in  actively immunized  arthritic  rats,  and  (b)  what 
component of serum was responsible for development of arthritis. 
* This study was supported by grants AM-00650 and AM-16506 from the U. S. Public Health Service 
and project directed funds from the Veterans Administration. 
I Abbreviations used in  this paper: RA,  rheumatoid arthritis;  PBS, phosphate-buffered saline; ELISA, 
enzyme-linked immunoassay;  OPD, ortho-phenylenediamine. 
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Materials  and  Methods 
Animals.  Female  Wistar  outbred  rats  (100-150  g)  were  obtained  from  Charles  River 
Breeding Laboratories,  Inc., Wilmington, Mass.,  housed in metal cages,  and fed  a  standard 
rodent chow diet with water ad libitum. 
Antigens and Immunization Methods.  Native type II collagen was  isolated by limited pepsin 
digestion of fetal bovine articular cartilage obtained fresh  from  a  local slaughter house and 
from a  rat chondrosarcoma known to produce type II collagen (12).  The tumor was the kind 
gift of Dr. George Martin  (National Institutes of Health).  Purification of collagen from both 
sources was performed in the same manner. Articular cartilage or tumor was dissected free of 
surrounding connective tissue and bone, minced with a sharp scalpel, and homogenized in 4 M 
guanidine hydrochloride  with a  homogenizer  (model  SD-45  with G-450 generator;  Tekmar 
Co.,  Cincinnati, Ohio)  kept  cold  with  an  ice  bath.  After  extraction  for  24  h  at  4°C,  the 
supernatant  fluid  was  collected  by  centrifugation  and  discarded,  and  the  precipitate  was 
washed  thoroughly with cold distilled water. The precipitate was subjected to limited pepsin 
digestion and the solubilized type II collagen was purified as previously described (13).  Amino 
acid analysis, uronic acid assay, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
showed  the  purified  type  II  collagens  to  be  free  of contaminating noncollagenous protein, 
proteoglycan, and type I collagen, respectively. The collagen was stored lyophilized in a vacuum 
desiccator at 4°C until used. 
In  experiments  using  radiolabeled  collagen,  bovine  type  II  collagen  was  acetylated  as 
previously described (10), except that [3H]acetic anhydride (5,000-10,000 mCi/mmol; Research 
Products International Corp., Mr.  Prospect, Ill.) was used instead of [X4C]acetie anhydride in 
order to obtain labeled collagen with higher specific activity. The resulting labeled collagen 
had a specific activity of 6.7 x  10  s dpm/mg. 
For immunization, type II collagen was dissolved in 0.01 N acetic acid at a concentration of 
2  mg/ml  by  stirring  overnight  at  4°C.  An  emulsion was  made  with  incomplete Freund's 
adjuvant and collagen solution at a ratio of 6:4 using a VirTis homogenizer (model 23; VirTis 
Co.,  Inc., Gardiner, N.  Y.)  at  high speed  for  2  min. Wistar rats were  given 0.1  ml of cold 
emulsion by intradermal injection of one hind footpad and received a  booster injection in the 
tail  1 wk  later  using another  identically prepared  emulsion. This  immunization procedure 
results ifi an incidence of arthritis of ~80% with a fairly uniform time of onset 12-16 d after the 
initial injection. The incidence and severity of arthritis and antibody levels are all greater than 
those achieved with the single injection we have previously reported (10). 
Preparation of Serum Concentrate.  Rats immunized with type II collagen were observed daily 
for the development of arthritis. Blood was obtained from nonarthritic rats by cardiac puncture 
and exsanguination of rats lightly anesthetized with ether on the day arthritis developed or on 
day 21. It was allowed to clot for 2 h  at  room temperature and the serum was recovered by 
centrifugation.  Arthritic  and  nonarthritic sera  were  pooled  separately.  A  gamma  globulin 
concentrate was  obtained by adding an equal  volume of saturated  solution of ammonium 
sulfate to the pooled sera, The resulting precipitate was recovered by centrifugation at  15,000 
g for 30 min. Distilled water was added to the precipitate dropwise so that it was resolubilized 
in a minimal volume. After dialysis against several changes of phosphate-buffered saline (PBS) 
for 24 h, the volume of the solubilized concentrate was adjusted to 50% of the starting serum 
volume  with  PBS.  The  concentrate  was  then  sterilized  by  filtration  through  a  0.22-/Lm 
microporous filter. This concentrate was either administered immediately to rats intravenously 
through a tail vein or stored frozen at -80°C until used. 
Immunoassay of Antibodies to Collagen.  Sera from rats not undergoing cardiac puncture were 
obtained  by retro-orbital  bleeding using a  capillary  tube.  An  enzyme-linked immunoassay 
(ELISA)  technique, adapted  from the methods described by Engvall and Perlman (14), was 
used to  measure antibody titers. A  similar method  for measuring antibodies to collagen has 
been described previously (15).  Round-bottomed 96-well microtiter plates  (Nunc,  Neptune, 
N.  J.)  were  coated  with  collagen  as  follows:  collagen  was  dissolved  in  0.4  ionic  strength 
phosphate buffer, pH 7.6, by stirring overnight at 4°C. The collagen concentration was adjusted 
to 5/~g/ml based on specific absorbance at  230 nm as detected by spectrophotometry.  Each 
well received  100/~1 of collagen solution and the plates were incubated at 4°C overnight. The 
coating solution was emptied by inverting the plate and sharply snapping the wrist to remove STUART ET AL.  3 
remaining  droplets. To reduce nonspecific adsorbtion, 100 #1 of 0.15 M NaCI, 0.02 M phosphate, 
pH 7.4 (PBS), containing  0.5% ovalbumin (Grade V; Sigma Chemical Co., St. Louis, Mo.) was 
added and incubation was continued for  1 h. Three additional washes  were performed with 
PBS containing 0.05% Tween 20 (PBS-Tween) and the plates were used immediately. 
For antibody assay,  sera were diluted with PBS-Tween containing 0.5% ovalbumin, and 
aliquots of 100 #1 were added to the type II collagen-coated microtiter plates. After incubation 
at 4°C overnight, the plates were washed three times with PBS-Tween, 100 #1 of a  1:1,000 
dilution of rabbit anti-rat IgG peroxidase conjugate (Cappel Laboratories, Inc., Cochranville, 
Pa.) was added, and incubation was continued for 4 h at room temperature. Excess conjugate 
was removed by washing three times with PBS-Tween and the amount of conjugate specifically 
bound was  determined by  adding orthophenylenediamine (OPD)  (Sigma  P  3888;  Sigma 
Chemical Co.)  as  a  substrate. After incubation at  room  temperature for  1 h,  the  reaction 
product  was  measured  by  absorbance at  492  nm  using an  automated  device  (Dynatech 
Laboratories, Inc., Alexandria, Va.). Optimal dilution of the conjugate was determined based 
on "checkerboard" titration under actual assay conditions. 
Substrate was prepared by dissolving 40 mg of OPD in 100 ml of 0.024 M citric acid, 0.05 
M  dibasic sodium phosphate, pH 5.0, and adding 40 #1 of 30% H202.  Because  OPD is light 
sensitive, substrate was always prepared immediately before use. 
Collagenase Digestion.  To determine whether immune complexes were involved in the devel- 
opment of arthritis, serum concentrate was subjected to collagenase digestion to remove the 
collagenous component of the presumed complex. Serum concentrate was dialyzed against 0.01 
M Tris, 0.15 M NaCI, pH 7.4, and made to contain 4 mM CaC12. Purified bacterial collagenase 
(kindly provided by Dr. Carlo Mainardi, Memphis Veterans' Administration Medical Center, 
Memphis, Tenn.) was added at a concentration of 10 U/ml and the solution was incubated for 
90  min at  37°C.  The  reaction was  terminated by addition of  10  mM  EDTA and  5  mM 
phenanthroline (final concentrations). To ensure that the collagenase was active and capable 
of digesting collagen from immune complexes,  an aliquot of immune serum was preincubated 
with 50 #g/ml of native type II collagen and then subjected to a similar collagenase digestion. 
The antibody titer of the immune serum was  determined before addition of collagen, after 
addition of collagen, and after collagenase digestion. 
Affinity Chromatography.  Because immune complexes were not detected in serum concentrate, 
further purification of the active principle was carried out by a combination of affinity and gel 
filtration chromatography. Native type II collagen was bound to CNBr-activated Sepharose 4B 
(Pharmacia Fine Chemicals,  Piscataway,  N. J.)  by  the  following procedure.  Collagen was 
dissolved in 0.4 ionic strength phosphate buffer, pH  7.6, at a  concentration of 2 mg/ml by 
stirring overnight at 4°C. CNBr-activated Sepharose was prepared by washing 1 g of the dry 
beads with 200 ml of 1 mM HC1 in a scintered glass funnel over a  15-min period. The moist 
beads  were  added  directly to  the  collagen solution and  the  suspension was  gently shaken 
overnight at 4°C using a rotator.  1 ml of 1 M  ethanolamine was added and incubation was 
continued for  1 h. The Sepharose conjugate was then washed alternately with PBS and 0.2 M 
glycine-HCl, pH  2.8,  for  three  cycles.  The  quantity of collagen bound to  the  beads  was 
determined by hydi'olyzing a  100-#1 aliquot and performing an analysis of hydroxyproline 
content as previously described (16). Under the conditions used, -0.6-1.0 mg of collagen/ml of 
Sepharose was bound. Finally the conjugated collagen-Sepharose was equilibrated with PBS 
and 3 ml of gamma globulin concentrate was added. After incubation overnight at 4°C, the 
suspension was placed in a  1- ×  6-cm polypropylene column and washed with PBS until no 
protein could be detected  in the eluate by spectrophotometry. All of the wash volume was 
collected (PBS eluate). Protein bound to the affinity column was eluted with 0.2 M  glycine- 
HC1, pH 2.8 (acid eluate), and dialyzed exhaustively against PBS. Both eluates were separately 
concentrated to 2 ml by pressure dialysis using a concentration cell equipped with a YM 30 
membrane (Amicon Corp., Lexington, Mass.)  and either applied to a column for gel filtration 
or  sterilized  by  microporous  filtration before  being given to  recipient rats  by  intravenous 
injection into the tail. 
Gel Filtration Chromatography.  The acid eluate from the collagen-Sepharose affinity column 
was applied to a  column (2.5  x  100 cm) of Biogel  A5m (BioRad Laboratories, Richmond, 
Calif.) that had been equilibrated with PBS  and calibrated using purified rat IgM and IgO SERUM TRANSFER OF COLLAGEN-INDUCED ARTHRITIS 
(Cappel  Laboratories, Inc.). A drop of tritiated water was mixed with each sample to serve as 
an internal marker for the column volume. The column effluent was continuously monitored 
at 280 nrn and fractions of 5 ml were collected. Fractions were pooled as indicated, concentrated 
by pressure  dialysis as  described  above, sterilized, and  given to recipient rats by intravenous 
injection into the tail. 
Immunoelectrophoresis and Immunodiffusion.  Immunoelectrophoresis was performed on agarose- 
coated  glass  microscope slides using a  Gelman  electrophoresis  apparatus  and  standard  tech- 
niques  (17).  Briefly, Noble Agar  (Difco Laboratories,  Detroit,  Mich.)  was  dissolved in  High 
Resolution Buffer (Gelman Sciences Inc., Ann Arbor, Mich.) at a  concentration of 1.5%. 3 ml 
of agar gel were applied to each clean 25- x  75-mm glass slide. Wells were punched in the agar 
and  filled  with  5-7  /xl  of sample.  After  the  antigen  solution  had  diffused  into  the  well, 
electrophoresis was performed at room temperature and 4 mA for 60 min.  1-mm troughs were 
removed and  antisera  were added.  Precipitin  lines were permitted  to develop over 48  h  in a 
humidified chamber at 4°C. 
Ouchterlony  immunodiffusion  was  performed  in  l%  Noble  Agar  (Difco  Laboratories) 
dissolved in 0.1  M  sodium acetate, pH 7.4.  1-mm holes separated by 4 mm were punched using 
a  template.  Holes were filled with antigen or antisera  at  room temperature  and  permitted to 
develop overnight. 
Inhibition Studies.  The specificity of the purified transfer antibody was examined by testing 
the ability of various collagens to inhibit its binding to bovine type II collagen-coated microtiter 
plates.  Each collagen tested was dissolved in 0.1  N  acetic acid at a  concentration of 1 mg/ml 
and  dialyzed  against  PBS  at  4°C.  When  denatured  collagen  was  used,  an  aliquot  of the 
respective native collagen was placed  in a  boiling water bath  for  10 min  to assure  thorough 
heat denaturation.  Appropriate  dilutions of each inhibitor were added  to aliquots of purified 
transfer antibody and  incubated  for 30 min at 4°C before testing for binding in the standard 
ELISA system. 
Results 
Passive  Transfer of Arthritis.  Gamma  globulin concentrate ofsera obtained from rats 
at the time of onset of collagen-induced arthritis  transferred  disease to  100% of naive 
recipients  if given  in  sufficient  concentration  (Table  I).  Control  gamma  globulin 
concentrate  obtained  from  animals  immunized  with  incomplete  Freund's  adjuvant- 
acetic acid  emulsion  was  not  effective in  transferring  disease.  In addition,  sera  from 
rats  immunized  with  type  II  collagen,  which  did  not  develop  arthritis,  would  not 
TABLE  I 
Passive Transfer of Arthritis 
Donor source 
Recipients 
Arthritic/total 
hnmunized with type II collagen 
Arthritic (2.5 ml)  12/12 
Arthritic (2.0 ml)  3/4 
Arthritic (1.5 ml)  0/4 
Nonarthritic (2.5 ml)  0/4 
Immunized with incomplete Freund's adjuvant-buffer (2.5 ml)  0/4 
Nonimmunized (2.5 ml)  0/4 
Donor rats were immunized with native type II collagen and bled on the day definite 
arthritis was first detected. Rats not developing arthritis and those receiving incom- 
plete  Freund's  adjuvant-buffer  were  bled  on  day  21  and  their  sera  were  pooled 
separately.  An equal volume of saturated solution of ammonium sulfate was added to 
each pooled serum and the precipitate was redissolved in water, dialyzed against  PBS, 
adjusted to 1:2 the original serum volume, sterilized,  and administered intravenously 
to nonimmunized recipients  in the amounts shown in parentheses. STUART  ET  AL.  5 
transfer disease when 2.5 ml of the concentrate was given to nonimmunized recipients. 
Quantities  larger than  2.5  ml could  not  be given because administration  of higher 
volumes resulted in an excessive rate of mortality in the recipients. 
Clinical  Course and  Histopathology  of Passively  Transferred  Disease.  Arthritis  in  the 
recipient rats developed within  18-72 h  after transfer. In the initial experiments, 67% 
(10/15)  of the recipients that developed arthritis did so by 24 h, with an additional 
27% developing disease by 48 h, and another 7% by 72 h. In addition, all of the rats 
that became arthritic by 24 h had bilateral hindpaw involvement. An example of one 
of these rats is shown in  Fig.  1. Of those animals that  became arthritic  between  24 
and  72 h, two had bilateral and three had unilateral  hindpaw disease. We have not 
observed forepaw lesions in any of the recipients.  Furthermore, disease has been less 
severe  than  in  the  immunized  donors.  It  has  consisted  primarily  of redness  and 
swelling of the ankle joint  and did not  extend into the small joints of the  digits.  In 
most of the arthritic recipients, the redness and swelling abated over a  period of 3-5 
d  (mean  duration  of arthritis,  4.7  -+  1.6  SD).  No  chronic  lesions  or  permanent 
deformity were noted. 
The  histopathology  of passively transferred  arthritis  was  similar  to  that  seen  in 
early  disease  of immunized  donors.  The  lesion  was  one  of synovial  proliferation, 
infiltration of subsynovial tissue with neutrophils and mononuclear cells, and exuda- 
FIG.  1.  Hind limbs from a rat that developed bilateral arthritis after transfer of serum concentrate 
from an arthritic donor,  Note the swelling of both ankles (A)  as compared with a  normal rat  (C) 
and increased thickness  of the dorsum of the foot (B) as compared with a normal rat (D). Photograph 
of the arthritic rat was taken 24 h after onset, 48 h after transfer. SERUM  TRANSFER  OF COLLAGEN-INDUCED ARTHRITIS 
Fro.  2.  Histology of the arthritis developing 24 h after passive transfer (A) as compared with that 
developing 14 d (B) after immunization with type II collagen. Both joints were obtained on the day 
of onset. Hematoxylin and eosin × 80 (A). 
tion of cells into the synovial space (Fig. 2). An early marginal erosion was seen in one 
of the joints examined histologically 24 h  after the onset arthritis (Fig. 3). Although 
the most frequent cell found in the synovial space was the neutrophil, a  substantial 
mononuclear cell  infiltration was  seen  in  the  synovial  tissue.  Vasculitis  was  not 
prominent in either the immunized donors or in the recipients. 
Humoral Immunity  to Collagen in Recipients.  Recipients were bled at  intervals after 
transfer  and  antibody levels  to  type  II  collagen  were  measured.  During the  first 
several hours after transfer, the levels were stable but they rapidly declined between 
24 and 48 h  and then more slowly declined over the next several days (Fig. 4).  Low STUART  ET  AL. 
Fro.  3.  A marginal erosion developing in a  rat with arthritis after passive transfer of serum from 
a  donor that had collagen-induced arthritis. Hematoxylin and eosin X 200. 
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FIG.  5.  Antibody levels in donor and recipient  rats  (24 h  after transfer). A  1:1,000 dilution was 
used for all sera tested. The mean ±  SEM for replicate samples of pooled donor serum is shown by 
shaded bars. The mean ±  SEM for four recipients is shown by an open bar. Each recipient received 
2.5 mt of donor serum concentrate. 
TABLE  II 
Antibody Levels by ELISA after CoUagenase 
Sample tested 
Absorbance 
1:500  1:5,000 
Sermn  1.402  0.136 
Serum +  collagen  0.287  0.068 
Serum +  collagen +  collagenase  1.304  0.110 
Serum +  coilagenase  I .',}45  0.112 
The  pooled  serum  used  in  transfer  experiments was  assayed  for  collagen 
binding after preincubation with 50 #g/ml collagen or 10 U/rot co]lagenase or 
both sequentially. The reaction was terminated by adding EDTA and phen- 
anthroline to each tube. Aliquots diluted in PBS  1:500 and  1:5,000 were then 
placed  on  collagen-coated  microtiter  plates  and  binding  was  measured  by 
ELISA. 
but detectable levels were still  present after 7 d, when arthritis had clinically resolved. 
Pooled sera from arthritic and nonarthritic donor rats were also examined for antibody 
levels  and these were compared with levels  in the sera obtained from recipients 24 h 
after  transfer.  The  antibody  levels  in  recipients  of sera  from  arthritic  donors  was 
higher  than  that  attained  in  recipients  of sera  from  nonarthritic  donors.  These 
experiments therefore did not determine whether the difference between arthritic and 
nonarthritic rats represented a  qualitative or merely a  quantitative difference in the 
antibodies produced (Fig.  5). 
Evidence against an  Immune Complex Etiology.  Because  in  initial  experiments  only 
serum concentrate from rats with acute arthritis was capable of transferring disease, 
and because the earliest lesion detected was one of synovial hypertrophy and synovitis, 
consideration was given to the possibility that the arthritis was caused by deposition 
of a  circulating  immune  complex  in  the  synovial  tissue.  To  test  that  hypothesis, STUART  ET AL.  9 
gamma globulin concentrate was incubated with bacterial collagenase in an attempt 
to destroy the collagenous portion of the presumed complex. After incubation with 10 
U  of collagenase  for 90  min  at  37°C,  the  concentrate  fully  retained  its  ability  to 
transfer disease.  To prove that  the collagenase was active and capable of digesting 
collagen bound to antibody, collagen was added to an aliquot of the concentrate and 
the  antibody  titer  was  determined  by  ELISA.  After  addition  of collagen  to  the 
antisera,  there was substantial  reduction  of the detectable antibody titer.  Digestion 
with  collagenase exactly as  performed in  the  aliquot  used  to  transfer disease, com- 
pletely restored the antibody titer (Table II). 
In a  separate experiment,  six  rats were  immunized with  collagen  that  had  been 
acetylated with [~H]acetic anhydride.  Four of these rats developed arthritis.  Sera (-3 
ml each) was obtained from the arthritic rats on the day arthritis was first detected 
and from the nonarthritic  rats on day 21.  Each of the sera was separately subjected 
to  50%  ammonium  sulfate  precipitation  and  the  precipitate  was  assayed  for  the 
presence of 3H. There was no increase in detectable radioactivity above background 
in any of the sera. 
Finally,  aliquots  of arthritic  sera  were  tested  for  CIq  binding  activity  (kindly 
performed by Dr. Tom Lawley, National Institutes of Health). All of the arthritic and 
normal  sera  showed  <10%  binding.  When  collagen  was  added  to  an  aliquot  of 
immune serum and CIq binding was measured, the level increased to 28%.  Normal 
serum heated to 60°C  for 10 min to cause aggregation of IgG showed 34% binding. 
Isolation  and  Purification  of the  Active  Principle.  Because  no  evidence  of  immune 
complexes was detected  in  arthritic  rat  sera,  the  gamma globulin  concentrate  was 
absorbed with a native bovine type II collagen affinity column to determine whether 
the active principle would bind to collagen. The PBS eluate, when concentrated to a 
volume of 2.5 ml and administered to a naive rat, could not transfer disease. An acid 
eluate was also obtained, dialyzed against PBS, and concentrated to 2.5 ml. The acid 
eluate  was  fully  active  in  transferring  disease.  This  result  was  verified  on  two 
additional  attempts.  Finally,  the acid eluate  from several affinity column  runs was 
pooled and subjected to gel filtration on Biogel A5m. The elution profile is shown in 
Fig. 6. Two major protein containing peaks were detected by absorbance at 280 nm. 
These  coincided  with  the  IgM  and  IgG molecular weight  markers.  In  addition,  a 
variable  small  peak  was  detected  in  the  void  volume.  Fractions  were  pooled  as 
indicated and pool III was found to transfer disease. None of the other pooled fractions 
could transfer disease. The active principle therefore eluted as a single peak coincident 
with the IgG marker. 
It was confirmed by immunoelectrophoresis that the major protein in the purified 
active fraction was actually IgG (Fig. 7). Ouchterlony gel diffusion was also performed 
and showed a band of identity between the active fraction and purified IgG. No IgM 
was detected using ~ chain-specific antisera and normal serum as a control. There was 
only one band present when the purified  fraction was tested against rabbit anti-rat 
whole serum. These data confirmed that the component of arthritic serum responsible 
for transfer was an IgG anticollagen antibody. 
Specificity of the Purified  Transfer Antibody.  Inhibition studies were performed using 
the  purified  antibody  preparation.  Aliquots  containing  1 ~g of antibody/ml  were 
preincubated with native and denatured bovine and rat type II collagen for 30 min 
and then assayed for binding to bovine type II collagen-coated plates in our standard 10  SERUM  TRANSFER  OF  COLLAGEN-INDUCED  ARTHRITIS 
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Fro.  6.  Elution profile of the acid eluate  from the type II collagen affinity column. The elution 
volume  (VE)  is  given  relative  to  tritiated  water  (I~¢rn~o) and  the  elution  volumes of calibration 
proteins-purified rat IgM and IgG are marked by vertical arrows. A  2.5-  ×  100-cm column packed 
with Biogel A5m was used. Fractions were pooled as indicated and concentrated by pressure dialysis. 
Only pool III would transfer arthritis. 
FIG.  7.  Immunoelectrophoresis of the purified  transfer material.  Purified  transfer material  was 
placed  in  the well  and electrophoresis was performed.  Rabbit  anti-rat  IgG,  7  chain specific, was 
placed in trough A and rabbit anti-rat whole serum was placed in trough B, Although the preeipitin 
line seen against the anti-IgG is heavier, a  pattern typical for rat IgG developed with no additional 
lines seen against anti-rat whole serum. 
ELISA assay. There was substantial cross-reactivity of the homologous native collagen 
with  the  bovine  type  II collagen  used  for  immunization  (Fig.  8).  Neither  of the 
denatured collagens was an effective inhibitor. 
Discussion 
There is considerable evidence that  collagen-induced arthritis  in rats results from 
the development of an immune response specific for native type II collagen. Several 
laboratories (18,  19)  have confirmed the observation that  immunization of rats with 
native type II collagen but  not  denatured collagen or other types of collagen results 
in the development of inflammatory arthritis.  In addition,  it has been reported that 
some strains of mice are also susceptible to type II collagen-induced arthritis (20).  We 
have now shown that purified IgG antibody to native collagen can transfer arthritis 
in rats. This passively transferred disease has all of the histopathologic characteristics 
of the  early  lesions  of animals  that  develop  disease  as  a  result  of immunization, !  ! 
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FIc.  8.  Inhibition studies. Purified transfer antibody,  1 ,ug/ml, was incubated with native bovine 
type  II  collagen  (O),  denatured  bovine  type II  collagen  (C)), native rat  type  II  collagen  (I),  or 
denatured rat  type II collagen  (D), and assayed for binding to native bovine type II collagen by 
ELISA. 
including synovial proliferation, subsynovial infiltration of neutrophils and mononu- 
clear cells, exudation  of cells into the synovial space, and development of marginal 
erosions. It has, however, been less severe than disease in immunized animals and was 
relatively transient.  This  may be related  to  the  use  of a  single  injection  of serum 
concentrate  to transfer disease. The effect of multiple serial injections  has not  been 
investigated. It is also possible that cellular mechanisms may contribute to the disease 
seen in immunized rats. 
Other  authors  have  reported  that  disease  can  be  transferred  with  cells  from 
immunized syngeneic donors (9).  However, they used a  relatively large number (6 × 
108-10  ×  I0  a)  of pooled  lymph  node  and  spleen  cells,  including  B  cells.  Because 
neither cellular sensitivity nor antibodies to collagen were detected in their arthritic 
recipients and because the transferred cell responsible for disease develoment was not 
identified, it is uncertain whether the passively transferred disease they describe results 
from a mechanism similar to that we have reported or from another mechanism. The 
authors in fact suggest that viable B cells may have been transferred and could have 
produced  antibodies in the recipients. Two additional  differences in their studies as 
compared with ours were (a) they found that disease could be transferred from either 
arthritic  or nonarthritic  donors,  and  (b)  only 40% of recipients developed arthritis. 
Because the arthritis incidence in their immunized donors was also 40%, it appeared 
that some rats were protected or actively suppressed disease development. Our studies 12  SERUM TRANSFER OF COLLAGEN-INDUCED ARTHRITIS 
suggest  that  most or all Wistar outbred rats will  develop disease if given sufficient 
antibody of the requisite type. 
The  question  of whether  cellular  sensitivity  to  collagen  is  sufficient  to  initiate 
arthritis or whether it will intensify or perpetuate disease has not yet been answered. 
Consideration was given to the possibility that the crude serum concentrate transferred 
in our experiments contained anti-idiotype antibodies or other mediators of cellular 
reactivity that could trigger a rapidly developing cellular response. Other investigators 
have shown  that  T  helper cells may be triggered by anti-idiotype antibodies  (21). 
However, lympocyte proliferation in response to collagen, a measure of cell-mediated 
immunity, was not detected in the arthritic recipients in our studies, whereas strong 
reactivity was readily detected in immunized donors (data not shown). Furthermore, 
it is unlikely that the immunoglobulin purified by collagen affinity chromatography 
contained anti-idiotype because anti-idiotype raised  in  a  syngeic system  is  usually 
binding site specific (22)  and epitope inhibitable  (23).  The most  important mecha- 
nisms of arthritis development in the rats that received serum in our studies appeared 
to be humorally mediated and independent of cellular sensitivity to collagen. 
There is circumstantial evidence that IgG anticollagen antibodies are also critical 
to the development of collagen-induced arthritis in mice. We have shown that arthritis 
in DBA/1  mice is temporally associated with high levels of IgG antibody specific for 
native type II collagen (24).  IgM antibody levels and cellular sensitivity to collagen 
were declining in these mice when arthritis occurred. Furthermore, only the antibodies 
were specific for native collagen.  Cellular sensitivity was  triggered by the  primary 
structural and not conformational determinants on the collagen molecule. When the 
susceptibility of various mouse strains to collagen-induced arthritis was tested, only 
mice that  developed high  levels of antibodies  to native type I! collagen developed 
arthritis (25), a relationship similar to that found among various strains of rats tested 
for susceptibility to collagen-induced arthritis (26). 
High levels of antibodies reactive with type II collagen are not the only determinant 
of arthritis development, however. It has been reported (2)  that although the mean 
antibody  level  in  arthritic  rats  is  higher  than  in  nonarthritic,  some  individual 
nonarthritic  rats  also  have  high  antibody  levels.  In  addition,  we  have  previously 
shown  (24)  that  DBA/1  mice, which  are  susceptible to collagen-induced arthritis, 
develop high antieollagen antibody titers when  immunized with denatured type II 
collagen.  These  antibodies  cross-react  with  native  collagen  but  the  mice  do  not 
develop arthritis  (24).  Finally, some mouse strains,  notably B10.S and  B10.D2, are 
high antibody responders when immunized with native type II collagen but are not 
susceptible  to collagen-induced  arthritis  (25).  Although  anti-type II  collagen  anti- 
bodies are always present in arthritic rats or mice, the reverse finding is not universal. 
Because antibody levels were not the only determinant of disease development, and 
because the arthritic lesion was one of synovial hypertrophy, whereas type II collagen 
is  located  in  the  cartilage  and  is  not  known  to  be  present  in  synovial  tissue, 
consideration was  given to the possibility that  circulating immune complexes were 
responsible for the development of arthritis. Several experiments were designed to test 
that  hypothesis.  All  of  these  experiments  consistently  failed  to  demonstrate  the 
presence  of circulating  immune  complexes.  The  arguments  against  a  circulating 
immune  complex etiology can  be  summarized  as  follows:  (a)  Digestion  of serum 
concentrate with bacterial collagenase failed to prevent transfer of disease. This could STUART ET AL.  13 
not  have  been  due  to  protection of the  collagen  by binding  to  antibody because 
control studies demonstrated that the collagen in collagen-antibody complexes formed 
in vitro were susceptible to collagenase.  (b) When isotopically labeled collagen was 
used to immunize rats, no label could be detected in acute sera or in arthritic joints. 
(c)  Direct testing of sera from acutely arthritic rats by CIq binding assay failed to 
demonstrate the presence of immune complexes. However, complexes formed in vitro 
by the  addition  of collagen  to immune serum were readily detected when  assayed 
simultaneously.  (d) It was unlikely that collagen-immune complexes would bind to 
an  affinity column,  be eluted,  and  reformed in  the eluate.  (e)  By molecular seive 
chromatography the active component of serum had a molecular weight identical to 
monomeric IgG, whereas immune complexes would be expected to be of substantially 
higher molecular weight. 
We therefore postulate that the arthritis observed after passive transfer was caused 
by circulating IgG antibodies that localized to the joint by combining with autologous 
collagen.  The  feasibility of this  occurring was  demonstrated  by inhibition  studies, 
which  showed  considerable  cross-reactivity  between  the  bovine  collagen  used  for 
immunization and rat type II collagen. Proof of this hypothesis, however, will depend 
upon identification of specific antibody in the joints of arthritic rats. The reason that 
the early lesion appears to be one of synovitis, when in fact the inciting antigen has 
been identified in cartilage but not synovium, remains unresolved. In addition, the 
presence of high antibody levels in the absence of arthritis among some immunized 
animals  needs  further investigation.  It  is  likely that  the  antibodies  produced  after 
immunization  with  a  protein  as  complex as  collagen  are  heterogeneous and  have 
specificities for more than one epitope. Perhaps antibodies to only one or a  limited 
number of these  epitopes  are  arthritogenic.  All  of the  rats  that  produce sufficient 
quantities of the critical antibody develop arthritis. In support of this possibility is the 
finding that serum concentrate would transfer disease to essentially all of  the recipients, 
which suggests that all individual rats were susceptible to disease development. 
These data also have relevance to human disease. They demonstrate that histologic 
changes similar to those associated with rheumatoid arthritis can be induced in rats 
by passive transfer of IgG anti-type II collagen  antibodies.  In  particular,  marginal 
erosions, long an unresolved dilemma in studies of human arthritis, can apparently be 
induced in  rats solely by anticollagen antibodies.  Because it  has been  reported by 
several investigators that antibodies to type II collagen are present in rheumatoid sera 
and synovial fluid  (8, 27), it is tempting to speculate that  pathophysiologic mecha- 
nisms similar to those in collagen-induced arthritis may be involved in RA. However, 
the precise specificity of the antibodies detected in RA is unknown. Most studies of 
RA have emphasized that stronger reactivity was detected in response to denatured 
collagen than to native collagen (8) and that the reaction was not necessarily specific 
for type II collagen (28). However, two reports of inhibition studies performed on RA 
sera selected for strong collagen reactivity suggested that at least some patients may 
have antibodies  that  are specific for type II collagen and  react  preferentially with 
conformationally  dependent  determinants  (29,  30).  Our  data  indicate  that  only 
antibodies of a particular, though as yet only partially characterized, specificity may 
be responsible for development of disease in rats and that in contrast to the reactivity 
usually detected in RA,  they are highly specific for native type II collagen. Further 14  SERUM  TRANSFER  OF COLLAGEN-INDUCED  ARTHRITIS 
studies  are  needed  to characterize  anticollagen  reactivity  in  both  rodents  and  man 
before analogies can be drawn. 
Summary 
We have found that serum from rats with type II collagen-induced arthritis,  when 
fractionated with 50% ammonium sulfate and concentrated, would transfer arthritis 
to nonimmunized recipients. The arthritis in recipients developed within  18-72 h and 
displayed  all  of  the  major  histopathologic  characteristics  of  the  early  lesion  in 
immunized  animals  but  was  transient  and  less  severe.  Although  consideration  was 
given to the possibility that a circulating immune complex was involved, no evidence 
of such a  complex was detected. 
Further  fractionation of the serum yielded an IgG anticollagen  antibody that was 
fully  active  in  transferring  disease.  The  antibody's  reaction  was  inhibited  by  the 
native  bovine  type II collagen  used  for immunization  of donors  and  the  antibody 
strongly  cross-reacted  with  homologous  type  II  collage  but  not  with  denatured 
collagen. 
These studies  demonstrate  that  arthritis  in  rats  can  be induced  with  anti-type  II 
collagen  antibodies  and  suggest  that  an  autoimmune  process  is  involved.  Because 
antibodies  to collagen have also been detected in human rheumatic diseases,  further 
investigation of the characteristics of collagen antibodies capable of inducing arthritis 
seems warranted. 
The authors thank Dr. Tom Lawley for performing the CIq binding assays, Dr. Carlo Mainardi 
for providing purified bacterial collagenase, Dr. George Martin for providing the rat chondro- 
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